Entire Portfolio
print

Composition of the portfolio as of September 30, 2014

Celgene   12.2%
Gilead   9.9%
Actelion   9.3%
Isis Pharmaceuticals   8.5%
Incyte   7.0%
Vertex Pharmaceuticals   5.0%
Medivation   4.7%
Alexion Pharmaceuticals   4.0%
Agios Pharmaceuticals   3.8%
Puma Biotechnology   3.8%
Novo Nordisk   3.4%
Pharmacyclics   2.8%
Regeneron Pharmaceuticals   2.8%
Synageva BioPharma   2.5%
Swedish Orphan Biovitrum   2.3%
Alnylam Pharmaceuticals   2.0%
Halozyme Therapeutics   1.9%
Radius Health   1.9%
Neurocrine Biosciences   1.6%
Receptos   1.3%
Immunogen   1.1%
Novavax   1.0%
Infinity Pharmaceuticals   1.0%
Glenmark Pharmaceuticals   0.9%
Clovis Oncology   0.8%
Ipca Laboratories   0.8%
Lupin   0.7%
Tesaro   0.6%
Bavarian Nordic   0.5%
Achillion Pharmaceuticals   0.4%
Theravance   0.4%
Theravance Biopharma   0.4%
Probiodrug 1)   0.2%
Endocyte   0.1%
     
     
Radius Health Warrants 23.04.2018   <0.1%
Radius Health Warrants 19.02.2019   <0.1%
Cubist Pharmaceuticals Contingent Value Rights - ex Optimer   <0.1%
Cubist Pharmaceuticals Contingent Value Rights - ex Trius   0.0%
     
Total Securities   CHF 2 880.9 mn
     
Other assets   CHF 50.7 mn
Other payables   CHF (159.4) mn
     
total shareholder's equity   CHF 2 772.1 mn
Treasury shares (in % of company) 2)   4.5%

 

1) Unlisted company

2) Correspond to the total of all own shares held including the second trading line